News Archive

The EXSCEL trial, which explored the impact of exenatide on major cardiovascular events in patients with Type 2 diabetes, has also published nearly a dozen secondary manuscripts on a range of topic

In response to a recent study that found the majority of cardiovascular patients are eligible for at least one of 12 novel secondary prevention therapies, representatives from the DCRI urge a focus on implementation of these therapies into clinical practice. The wide range of new therapies for cardiovascular secondary prevention raises questions about the best way to use these therapies in clinical practice and underscores the need for novel approaches to implement these therapies into routine patient care.

The observational study found that amongst acute ischemic stroke patients treated with intravenous tissue plasminogen activator, patients who had experienced a previous stroke within the past two w

The HARMONEE trial is part of the Harmonization by Doing program, which aims to create a uniform pathway for clinical development in the U.S. and Japan.

A new analysis from the DCRI showed that 35 percent of direct costs related to musculoskeletal pain were attributable to about 4 percent of patients who were persistent high-cost utilizers.

The initiative, which will be led by a DCRI pediatrician, aims to create a new care and services model for children in five North Carolina counties.

As the year—and the decade—draws to a close, we take a look back at some of our accomplishments and the ways in which we shared knowledge in 2019.

The survey focused on invasive cardiac care and measured patient knowledge, goals, and concerns related to these procedures.

Study results recently published in Neuropsychopharmacology indicate that young adults with ADHD are at higher risk of becoming addicted to nicotine after even the first exposure to the substance. The study included 136 non-smokers between ages 18 to 25, about half of whom had a clinical diagnosis of ADHD. Participants were administered two different doses of nicotine and a placebo.

The Antibacterial Resistance Leadership Group conducts clinical research to better understand how to diagnose, treat, and prevent antibacterial resistant infections.